radiotherapy in carcinoma ovary
TRANSCRIPT
RADIOTHERAPY IN CARCINOMA OVARY DR. DEBASHIS PANDA SENIOR RESIDENT DEPARTMENT OF RADIOTHERAPY LOK NAYAK HOSPITAL PRECEPTORS- DR. K. SINGH DR. A. SRIVASTAVA
1
INTRODUCTION
Contemporary strategies
Surgical exploration
Staging, and cytoreduction
Chemotherappy- most often platinum and paclitaxel based adjuvant chemotherapy
Radiation therapy, known since 1912 to induce long term remission in certain patients with ovarian cancer.
RT has largely been excluded from routine use now.
2
What NCCN says…
3
RADIATION IN PRIMARY OVARIAN CANCER
Methods-
Localized pelvic radiation
Abdominopelvic radiation
Intraperitoneal radiocolloids
In reviewing the utility of primary irradiation as a sole treatment modality in ovarian cancer, it is useful to discuss its role, separately in,
Early stage
Advanced stage
4
SIGNIFICANCE OF RT
Is there conclusive evidence that radiation therapy induces tumor cell kill in patients with ovarian cancer?
Residuum
Study End Point <2 cm >2 cm
Dembo % 10 yr relapse free 38% 6%
Martinez % 15 yr freedom from relapse 50% 14%
Fuller % 10 yr relapse free 62% 0%
Weiser % 10 yr survival 42% 10%
Goldberg 6 yr survival fraction 0.41 —
Thomas G. Dembo A: Integrating radiation therapy into the management of ovarian cancer.
Cancer 71:1710–8, 1993
5
CT Vs RT
How do the results of APRT compare with those achieved with conventional chemotherapy?
No head to head trials between
APRT Vs Paclitaxel based chemotherapy.
6
CT Vs RT
How do the results of APRT compare with those achieved with conventional chemotherapy?
No head to head trials between
APRT Vs Paclitaxel based chemotherapy.
7
Someone had thought for
Prospective evaluation of APRT versus cisplatin chemotherapy
Stage IA/B grade 2 or 3; stage IC through FIGO
Stage IIA/B through EORTC
END POINTS= SURVIVAL and QOL.
However, because the survival rate in this subgroup of patients is 80% or better at 5 years, conclusions regarding these endpoints are years off.
A. Files et al, European Journal of Cancer Part A. 1997;33(1):12-19.
8
CT+RT
4 X Cyclophosphamide and Hexamethylmeamine A/W 4 X concurrent cisplatin, whole abdominal radiotherapy, and intraperitoneal Misonidazole.
The entire treatment program lasted 6 months.
This outcome was no different than the previous experience with combination chemotherapy(NONCISPLATIN) performed by the same group.
N= 28
Stage III or IV
epithelial ovarian
carcinoma.
CR 50%
RESPONSE RATE 61%
pCR 18%
MEDIAN SURVIVAL 15.2 MONTHS
9
WART AS CONSOLIDATION THERAPY
Rationale- 40% to 60% of patients achieving a pCR after chemotherapy ultimately recur and succumb.
Consolidation Regimens Additional intravenous chemotherapy
Intraperitoneal chemotherapy
Intraperitoneal radiocolloids
Intraperitoneal immunoconjugates (Cederkrantz E et al, Int J Radiat Oncol Biol Phys. 2015 Nov 1;93(3):569-76.)
Hormones
High dose chemotherapy
Abdominopelvic RT would be a reasonable choice to affect this recurrence rate, if given after primary induction chemotherapy. (Fuks Z et al.Int J Radiat Oncol Biol Phys 8: 903, 1982. & Mychalaczak B. Hematol Oncol Clin North Am 6: 895, 1992. Thomas G. Gynecol Oncol 51: 97, 1993)
10
Game changer
Introduction of Cisplatin almost closed the trials of radiotherapy in Ovarian carcinoma.
In this Platinum era, very few prospective trials are there for RT as consolidation therapy.
Benefit from consolidation depends on residual tumor size.
11
Swedish Norwegian Ovarian Cancer Study
In this latter stratification, no difference in survival was demonstrated. In the former, however, a significant improvement in disease free survival was noted for abdominal pelvic radiation therapy, although follow up is premature.
N=
172
4
X
CDDP
&
DOXO
SECOND
LOOK
LAPARO-
TOMY
RE
SID
UA
L NON or
MICRO
MACRO
(74)
CHEMO
APRT
OBSER
APRT
CHEMO
12
BenBaruch and colleagues
In this trial, no significant difference was observed between the treatment arms initially;
however, in this updated report with now 5years of minimum followup, a nonsignificant trend to poorer survival was seen in the APRT arm
In addition, these authors report that survival after secondary recurrence was reduced significantly in those patients receiving APRT as their initial salvage regimen.
BenBaruch et al. Eur J Gynecol Oncol 15: 272, 1994
N= 37
SECOND
LOOK
LAPARO-
TOMY
INTRAPERITONEAL CDDP , THIOSULPHATE
APRT (N= 19)
13
Pickel et al (Gynecol Oncol 68:119 (abstract 192), 1998)
Of the 64 patients randomized, 58 had stage III or IV disease at presentation.
PFS at 10 years was significantly higher in APRT arm (50% vs. 30%, p = 0.012).
OS at 10 years was significantly higher (62% vs. 38%, p = 0.029) in the APRT arm.
Subset analysis of the stage III/IV patients was comparable.
N= 64
FIGO- ICIV
MAXIMAL
CYTOREDUCTIO
N
6
X
CARBO
EPIRUBICIN
PREDNIMUSTINE
NO
RE
SID
UA
L
APRT
OBSER
14
Recently
15
A retrospective analysis
n= 27 for IFRT, n= 14 for NIFRT (control cohort)
Tumour volume-directed IFRT for localized extraperitoneal recurrences (either as consolidation after cytoreductive surgery (CRS) or as attempted salvage if unresectable)
All patients were heavily pretreated with multiple chemotherapy
Involved field radiation therapy was primarily with external beam (median dose, 50.4 Gy).
Technique- 3-dimensional conformal techniques in over half the patients with the remaining receiving 2-dimensional RT.
Local recurrence-free survival (LRFS) was defined as freedom from in-field recurrences and was considered as a measure of effectiveness of radiotherapy
16
17
Of 27 patients, 17 had optimal CRS before RT.
None of the NIFRT patients survived beyond 5 years from initiation of salvage chemotherapy.
Yahara et al, maximal benefit in tumour size less than 3 cm. (J Radiat Res. 2013;54:322–329)
18
5 years 10 years
LRFS 70% 60%
OS 30% 19%
DFS 33% 20%
Conclusion on WPRT as Consolidation therapy
Toxicity in this setting is significant.
Patients without any residual disease will have more benefit.
It will be very premature to comment on survival data from these trials.
Presented data are still inconclusive, in spite that we can try IFRT in highly selected patients.
19
Salvage WPRT in Epithelial Ovarian Cancer
Reddy et al. IntJ Radiat Oncol Biol Phys 27: 879, 1993
Cases who have failed to one or more chemotherapeutic regimens. (N= 30)
2 groups- with microscopic(n=16) and with macroscopic(n=14) residual disease.
Subjected to WART (2500 cGy) f/b pelvic and paraaortic boost (2500 cGy)
Only 2 patients were unable to complete the planned therapy.
Another 26% of the patients required interruption of the therapy secondary to hematologic toxicity but eventually completed the treatment.
20
With an overall median follow-up of 14 months 56% of the patients remain alive.
Two-year actuarial survival and recurrence-free survival rates are 47 and 32%, respectively.
The survival and recurrence-free survival rates for the group with microscopic residual disease--61 and 33%, respectively--are better than those for the patients with macroscopic residual disease--36 and 18%.
The abdominopelvic cavity was the first site of failure.
In spite of the higher doses, pelvic failure alone or as a component occurred in 54% of the patients.
Small bowel obstruction necessitating surgical intervention as a complication of therapy was seen in 13% of the patients.
Conclusion Whole abdominal radiation is unlikely to benefit those patients with macroscopic
disease, and only those patients with localized microscopic pelvic disease stand to gain from this treatment.
21
Indications of RT
In good risk patients with stage I, grade I disease, adjuvant RT not required.
For patients with macroscopic disease in the abdomen and bulky disease in the pelvis (gross stage III and IV), RT is not a curative form of treatment.
Maximum benefit of post op RT is in patients with small volume (< 2 cm) residuum in the pelvis and without macroscopic disease in abdomen in salvage.
As a consolidative treatment in bulky post op residuum cases.
In palliative intent in cases of refractory or recurrent cases and also in cases of metastases.
22
Radiotherapy
Now it is a history for routine use, unless otherwise specified.
Target - Whole abdominal cavity and pelvis.
Patient position- Supine/ Prone
Portals- AP/PA
Field borders for WART Superior- 1.5 to 2 cm (above diaphragm)
Inferior- inferior border of obturator foramen
Lateral- whole peritoneum with a margin of subcutaneous tissue
Techniques Moving strip technique (MST) (Delclos, 1963)
Martinez technique/ Open field technique (Martinez et al. J Clin Oncol 3:901-902, 1985)
Modified Martinez technique.
23
Techniques
MST Dose Small fraction size 100- 125 cGy
daily is ideal for whole abdominal field. (Princess Margaret Hospital, Toronto, Canada, 1976)
At PMH- 2500- 2750 cGy WART f/b 2000- 2250 cGy boost to Pelvis.
25-30 Gy in 20# over 4 weeks + Pelvic Boost 20 Gy/ 10# over 2 weeks.
Both kidneys are shielded from posteriorly with 2 HVL and right half of liver is shielded with 1 HVL from both AP/PA.
24
Techniques
MARTINEZ Doses WART- 30 Gy in 20 # over 4
weeks the Pelvic boost in phase I, 9 Gy in 5#, in Phase II (T- Field) 12 Gy in 8#
Full thickness kidney shield applied posteriorly after 10 Gy and a 50% transmission block for liver after 15 Gy in both AP/PA.
Total liver dose 22.5 Gy in 23 #, total kidney dose 20 Gy in 20 #.
25
Techniques
Modified Martinez
Field and borders remain the same.
Except that the para-aortic boost field is omitted.
Used in cases with suspected bowel compromise
WART- 22 Gy/17#
Diaphragmatic boost- 15 Gy
Pelvic Boost- 24 Gy by 4 field or box technique
26
Radiotherapy
Pelvic field borders-
Superior- L5- S1 junction
Inferior- lower border of obturator foramen
Laterally- 1.5 cm beyond the true boney pelvis.
27
Complications of RT
Acute-
Small bowel symptoms
Nausea & vomiting
Bone marrow suppression
Late-
Adhesions
Perforation
Peritonitis
28
RADIOACTIVE CHROMIC PHOSPHATE (P-32)
Pure beta emitter.
Improved tumour penetration.
Less hazard to treating personnel.
Has been used since early 1950s.
Intraperitoneally at a dose of 10 to 20 mCi mixed in 1 to 2L of saline.
Before instillation of the active P-32, a technetium scan usually is performed to determine whether distribution of the colloid in the abdominal cavity is satisfactory.
29
Radioactive Chromic Phosphate in Primary Therapy
Several investigators have studied this therapy in combination with other modalities, such as chemotherapy (nonplatinum) or pelvic radiation.
because of significant complications, they have concluded that this agent is best considered singly.
Soper J, Wilkinson R, Bandy L et al: Intraperitoneal chromic phosphate P32 as salvage therapy for persistent carcinoma of the ovary after surgical restaging. Am J Obstet Gynecol 156: 1153, 1987
30
As consolidation therapy
It is clear that volume of residual disease is an important predictor of response.
No much improvement in survival.
Toxicity is high, some require surgical intervention.
31
Palliative therapy
For stage IV patients, and in metastatic cases
Dose and field depends on the site of the disease.
32
Reference
33
1.
2.
3. NCCN version 2.2015
4.
5.
Devita Clinical Oncology 10th edition
Text book of Radiation Oncology, principles and practice-
Rath & Mohanty
T H A N K U
34